Diversified Trust Co Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Diversified Trust Co lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 37.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 37,532 shares of the medical device company’s stock after selling 22,749 shares during the quarter. Diversified Trust Co’s holdings in DexCom were worth $2,516,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Cetera Advisor Networks LLC increased its stake in shares of DexCom by 24.5% in the 4th quarter. Cetera Advisor Networks LLC now owns 35,920 shares of the medical device company’s stock worth $4,457,000 after acquiring an additional 7,073 shares in the last quarter. Personal CFO Solutions LLC lifted its holdings in shares of DexCom by 6.5% during the fourth quarter. Personal CFO Solutions LLC now owns 3,548 shares of the medical device company’s stock valued at $440,000 after purchasing an additional 218 shares during the last quarter. Ossiam boosted its position in shares of DexCom by 12.6% in the 4th quarter. Ossiam now owns 15,377 shares of the medical device company’s stock worth $1,908,000 after purchasing an additional 1,722 shares in the last quarter. Connectus Wealth LLC purchased a new stake in shares of DexCom in the 4th quarter worth approximately $207,000. Finally, Elo Mutual Pension Insurance Co increased its position in DexCom by 4.8% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 33,992 shares of the medical device company’s stock valued at $4,218,000 after buying an additional 1,548 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock valued at $126,390 in the last ninety days. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $68.62 on Tuesday. The firm has a market cap of $27.29 billion, a PE ratio of 44.27, a PEG ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company’s 50 day moving average price is $70.19 and its two-hundred day moving average price is $104.75. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the company earned $0.34 earnings per share. The company’s quarterly revenue was up 15.3% on a year-over-year basis. Equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of several analyst reports. Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Morgan Stanley lowered their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.